Trending

FibroGen

GSK’s kidney disease anaemia drug approved in Japan, taking on Astellas’ rival

GSK’s kidney disease anaemia drug approved in Japan, taking on Astellas’ rival

GlaxoSmithKline’s drug for anaemia caused by chronic kidney disease daprodustat has been approved in Japan, taking on a recently approved rival from Astellas. Marketed

X

GSK’s kidney disease anaemia drug approved in Japan, taking on Astellas’ rival

https://pharmaphorum.com/news/gsk-kidney-disease-anaemia-drug-approved-in-japan-taking-on-astellas-rival/

AZ preps for US filing of kidney disease anaemia drug

AZ preps for US filing of kidney disease anaemia drug

AstraZeneca is gearing up for a US filing for its roxadustat, a potential drug for patients with anaemia

X

AZ preps for US filing of kidney disease anaemia drug

https://pharmaphorum.com/news/az-preps-for-us-filing-of-kidney-disease-anaemia-drugs/

Astellas gets nod in Japan for roxadustat, ahead of GSK rival

Astellas gets nod in Japan for roxadustat, ahead of GSK rival

Astellas has its first approval for roxadustat, getting a green light in Japan for the drug as a

X

Astellas gets nod in Japan for roxadustat, ahead of GSK rival

https://pharmaphorum.com/news/astellas-gets-nod-in-japan-for-roxadustat-ahead-of-gsk-rival/

AstraZeneca shows cardiovascular safety for roxadustat

AstraZeneca shows cardiovascular safety for roxadustat

AstraZeneca has announced that pooled analyses of the phase III trials for its kidney disease drug roxadustat confirm

X

AstraZeneca shows cardiovascular safety for roxadustat

https://pharmaphorum.com/news/astrazeneca-shows-cardiovascular-safety-for-roxadustat/

Galapagos and FibroGen drugs offer hope in IPF

Galapagos and FibroGen drugs offer hope in IPF

Drugs improve on existing medicines from Boehringer and Roche.

X

Galapagos and FibroGen drugs offer hope in IPF

https://pharmaphorum.com/news/galapagos-fibrogen-ipf/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com